Shilpa Medicare Intrinsic Value
SHILPAMED Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹484.00 | ₹387.20 - ₹580.80 | +58.3% | EPS: ₹22.00, Sector P/E: 22x |
| Book Value Method | asset | ₹764.25 | ₹687.83 - ₹840.68 | +150.0% | Book Value/Share: ₹2364.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹611.40 | ₹550.26 - ₹672.54 | +100.0% | Revenue/Share: ₹1488.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹611.40 | ₹550.26 - ₹672.54 | +100.0% | EBITDA: ₹440.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹764.25 | ₹611.40 - ₹917.10 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹140.80 | ₹126.72 - ₹154.88 | -53.9% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹339.90 | ₹305.91 - ₹373.89 | +11.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹611.40 | ₹550.26 - ₹672.54 | +100.0% | ROE: 7.4%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹917.10 | ₹825.39 - ₹1008.81 | +200.0% | EPS: ₹22.00, BVPS: ₹2364.00 |
Want to compare with current market value? Check SHILPAMED share price latest .
Valuation Comparison Chart
SHILPAMED Intrinsic Value Analysis
What is the intrinsic value of SHILPAMED?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Shilpa Medicare (SHILPAMED) is ₹611.40 (median value). With the current market price of ₹305.70, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹140.80 to ₹917.10, indicating ₹140.80 - ₹917.10.
Is SHILPAMED undervalued or overvalued?
Based on our multi-method analysis, Shilpa Medicare (SHILPAMED) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.61 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.40 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 7.4% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 29.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.45x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Shilpa Medicare
Additional stock information and data for SHILPAMED
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹132 Cr | ₹33 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹137 Cr | ₹52 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹180 Cr | ₹64 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹105 Cr | ₹-38 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹47 Cr | ₹-155 Cr | Positive Operating Cash Flow | 6/10 |